A modern psychedelic revolution is underway. Following the opening of cannabis legalization gates and the reduction of stigmas associated with medical marijuana, in particular, a renewed interest in entheogens as a medicine arose.
The last two years have seen a boom in the number of psychedelic companies working to transform the face of healthcare, with more trials than ever before on everything from psilocybin to DMT, treating a wide range of disorders and diseases.
In November Wonderland Psychedelic business conference, many of the best and brightest in the industry came down to Miami to share their progress, learn from each other and showcase the latest developments in this fast-paced emergency space.
Presented by Microdose, the first annual event drew nearly 2,000 entrepreneurs, thought leaders and investors over two days of engaging panels, captivating activations and networking opportunities.
Held at the Adrienne Arsht Center for the Performing Arts, the multifaceted agenda covered a wide range of topics.
Speakers spoke about psychedelic therapies for everything from PTSD addiction, the current investor landscape, cutting-edge scientific discoveries, and the state of political reform.
A workshop on ways entheogens can improve your sex life led a crowd just standing in the green room of the venue, with an overflowing crowd heading out into the lobby.
Boxer Mike Tyson and former NHL player Daniel Carcillo spoke in front of a packed audience about his personal successes with psychedelics as a way to deal with the physical and psychological trauma he has suffered in his professional and personal life.
Tyson, who has admitted to smoking Bufo alvarius toad poison 60 times in recent years, blames entheogens for making him a better person, but insisted his presence in space is greater than he is. The revelation went viral after the former world champion told the crowd that he “died” during his first toad experience.
“I’m very proud to be here today to share my opinion on medicine that made me who I am, but that’s all about the universe; that’s nothing about me,” Tyson said. Cannabis and technology today.
When asked how people can support the psychedelic medicine space, Tyson said:
“Don’t believe my word, just do it,” encouraging everyone to try entheogens for themselves.
Avant-garde research and development on display
The rapid pace of scientific discovery in the psychedelic realm was a hot topic at the Wonderland conference with several listed companies and organizations presenting their latest advances.
At a press conference this morning, members of Cybin’s leadership team provided updates on the creation of a new psilocybin analog. The drug, currently called CYB003, is designed to mimic the magic mushroom experience, but with shorter onset and duration, which the company believes will make the drug more accessible.
The company plans to enter CYB003 clinical trials in 2022.
“I’m really surprised by the progress,” Cybin said CEO Doug Drysdale Cannabis and technology today. “From the discovery of a molecule to the submission of IND to the FDA it could take normally three years. We’ll get there in about 15 months, which is tremendous.”
Dr. Joe Tucker, general manager of Enveric Biosciences, spoke at the panel “Next-Level Psychedelics,” sharing the multitude of ways in which his company seeks to expand the potential of entheogen-based therapies.
“We’ve actually started looking for non-hallucinogenic molecules, the ones that have the same deep ability to reconnect the brain but without the visual and auditory hallucinations.”
Rick Doblin, the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS), shared his insights into the state of the industry with CEO Amy Emerson in a conversation with Microdose founder Patrick Moher.
When asked about the intersection of sacred medicine and pharmaceutical capitalism, Doblin insisted that there is room for all interpretations as long as people are healing.
“You can have clinical-based treatments at the same time as religious use. I think there will be a parallel,” Doblin said, referring to a Brazilian study in which ayahuasca was administered in a hospital setting to patients with depression. remarkable success.
“Medicine is covered by insurance, not religion,” Doblin said.
The Microdose Awards highlight the best and brightest
One of the highlights of the Wonderland event was the announcement of the winners of the first annual Microdose Awards.
The awards recognize the outstanding achievements of both individuals and organizations throughout the psychedelic space in a wide range of categories.
Winners included Paul Stamets (Public Figure of the Year), Robin Carhart-Harris (Academic of the Year), Mojo Microdose of Gwella (Consumer Product of the Year) and Cybin (Company of the Year).
Writer Michael Pollan, whose work on psychedelic herbal medicine has won international acclaim, received two awards: Author of the Year and Industry Pioneer Lifetime Achievement Award.
“The public has recognized and appreciated Michael’s first-person research to learn what psychedelic drugs should teach him not only about the mind but also about his mind, and specifically about the nature of the spiritual experience,” he said. dir Moher.
Microdose Planning more face-to-face events, online programming continues
The success of the inaugural Wonderland conference means that the organizers are already looking forward to planning the next iteration. Doblin, who had initially rejected the idea of attending a psychedelic business conference, was surprised by the turnout.
“What surprised me was how many people came [to Wonderland] from all over the world! “he said.” It’s been an amazing opportunity. “
For those who want to get in touch with Microdose before the next conference is announced, the platform’s popular monthly Psychedelic Capital series is a great way to learn virtually about booming space. Archived programming is also available online.